Here, we aimed at establishing a proof of concept that a clinically relevant bispecific antagonist of PTGDR-1 and PTGDR-2 could be efficient to treat murine lupus-like nephritis. The gene discussed is PTGDR2; the disease is systemic lupus erythematosus.